Previous 10 | Next 10 |
- Adds More Than 25 Years of Financial Leadership in Pharma / Biotech to the Team - - To Chair iBio’s Audit Committee and be Appointed to the Board’s Compensation Committee - BRYAN, Texas, Oct. 15, 2020 (GLOBE NEWSW...
- Senior Biopharm Executive with 20 Years of Immuno-Inflammatory Disease Therapeutic Experience - -To be Appointed to the Board’s New Science & Technology Committee - BRYAN, Texas, Oct. 15, 2020 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (ȁ...
- Accomplished Biopharm Exec with Years of Clinical Experience in Respiratory Diseases - - To be Appointed to the Board’s New Science & Technology Committee - BRYAN, Texas, Oct. 14, 2020 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or th...
Cyclerion Therapeutics (CYCN) -41% after Phase 2 STRONG-SCD study results in patients with Sickle Cell Disease.Sorrento Therapeutics (SRNE) -12%.Aethlon Medical (AEMD) -11%.Enzo Biochem ENZ -10% on FQ4 earnings results.Auris Medical Holding (EARS) -10%.SOS ...
iBio (IBIO): FY GAAP EPS of -$0.61 beats by $0.01.Revenue of $1.64M (-18.8% Y/Y) beats by $1.04M.Shares -3.57%.Press Release For further details see: iBio EPS beats by $0.01, beats on revenue
BRYAN, Texas, Oct. 13, 2020 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a biotech innovator and biologics contract manufacturing organization, today announced its financial results for the fiscal year ended June 30, 2020, which incl...
It's the first confirmed case of a U.S. patient becoming reinfected with COVID-19, and the fifth known case reported worldwide.The 25-year-old man, who was a resident of Washoe County in Nevada, became seriously ill following the second infection, a study in the Lancet Infectious Diseases jou...
The head of the Trump administration's Operation Warp Speed program, Moncef Slaoui, expects drugmakers to file with the FDA for emergency authorization of a coronavirus vaccine by late November.The project aims on delivering 300M doses of a vaccine starting in January, though none of the four...
A recent 10-Q for IBIO mentions the word "plasma" just once. IBIO isn't a plasma company like ADMA and isn't developing a plasma-derived product for COVID-19 like KMDA. IBIO can make proteins in plants, such as plasma proteins, so can other. IBIO is late to the game with a recent ...
iBio (IBIO) is up 2% premarket, after regaining compliance with NYSE American continued listing standards.By meeting the requirements of the $50M market capitalization, the company has resolved its continued listing deficiency with NYSE. For further details see: iBio regains c...
News, Short Squeeze, Breakout and More Instantly...
– The sale of the facility eliminates $13.2M of secured debt – – Completes iBio’s transition to an AI and precision biologics innovation company - SAN DIEGO, June 03, 2024 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or th...
2024-05-28 07:30:05 ET Chardan Capital analyst issues BUY recommendation for IBIO on May 28, 2024 05:34AM ET. IBIO was trading at $2.19 at issue of the analyst recommendation. The overall analyst consensus : HOLD. Current analyst recommendations are : 1 - Hold recommenda...
Strengthened cash position with investment by healthcare specialist investors Expanding into cardio-metabolic space through AstralBio collaboration BRYAN, Texas and SAN DIEGO, May 13, 2024 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company...